Targeted Protein Degradation: How PROTACs and Molecular Glues Are Redefining Drug Discovery Strategies
Targeted Protein Degradation: Redefining Drug Discovery StrategiesTargeted protein degradation has emerged as a transformative approach in drug discovery, offering a way to eliminate disease-causing proteins rather than simply inhibit their activity.
Two main modalities dominate the field: proteolysis-targeting chimeras (PROTACs) and molecular glues. Both exploit the cell’s ubiquitin–proteasome system to mark unwanted proteins for destruction, opening therapeutic possibilities for previously “undruggable” targets.
How PROTACs and molecular glues work
PROTACs are bifunctional molecules that physically link a target protein to an E3 ubiquitin ligase, promoting ubiquitination and subsequent proteasomal degradation. Molecular glues are smaller, often monovalent molecules that stabilize or induce interactions between a target and an E3 ligase, similarly resulting in degradation. Key E3 ligases used in current strategies include cereblon and VHL, although efforts to expand the ligase toolbox are active to broaden tissue specificity and tackle resistance.
Advantages over traditional inhibition
– Catalytic mechanism: A single degrader molecule can prompt multiple rounds of target degradation, potentially lowering dosing requirements.
– Targeting scaffolding functions: Degraders can eliminate non-enzymatic or scaffolding proteins that are hard to inhibit with classic small molecules.
– Overcoming mutation-driven resistance: Removing a protein entirely can deny cancer cells or pathogens the ability to bypass inhibition via compensatory mutations.
Challenges drug discovery teams face
Despite promise, several challenges persist:
– Ternary complex dynamics: Successful degradation depends on forming a productive ternary complex (target–PROTAC–E3). Predicting and optimizing this interaction requires detailed structural and biophysical understanding.
– Pharmacokinetics and permeability: PROTACs often have high molecular weight and polar surface area, complicating oral bioavailability and tissue penetration.
Medicinal chemistry strategies to balance permeability, metabolic stability, and target engagement are essential.
– Selectivity and off-target degradation: Proteomics-based profiling is needed to identify unintended substrates and mitigate toxicity.
– E3 ligase expression variability: Tissue-specific expression of chosen ligases affects efficacy and safety, so selecting an appropriate ligase for the disease context is critical.
Best practices for discovery teams
– Structure-guided design: High-resolution structural data of target and E3 ligase complexes inform linker length and exit vector decisions. Cryo-EM and X-ray crystallography accelerate rational design.
– Functional cellular assays: Use concentration-response degradation assays, time-course studies, and orthogonal readouts (western blot, mass spectrometry) to characterize degradation kinetics, hook effect, and Dmax.
– Proteome-wide safety profiling: Tandem mass tag (TMT) proteomics and chemoproteomics reveal off-target effects early, guiding selectivity optimization.
– Expand the ligase portfolio: Screening covalent recruiters and tissue-selective ligase binders reduces reliance on a small set of ligases and can unlock new therapeutic windows.
– Leverage physiologically relevant models: Organoids and microphysiological systems help assess tissue-specific pharmacology and predict toxicity better than traditional monolayer cultures.
Outlook for drug discovery pipelines
Targeted protein degradation is evolving from a niche strategy into a broader platform that influences hit discovery, lead optimization, and translational research.
Integration of high-quality structural biology, sophisticated cellular assays, and modern medicinal chemistry is enabling teams to convert challenging biological hypotheses into drug-like degraders. As technologies to measure and predict ternary interactions and tissue distribution improve, targeted degradation is set to become a mainstay in efforts to tackle complex diseases that resist traditional approaches.
